Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!
01 Overview of Global Digital Health Investment and FinancingCore Sound Imaging, a provider of medical imaging workflow solutions, raises $80 millionOn January 16, Core Sound Imaging, a provider of medical imaging workflow solutions, secured $80 million in funding led by PSG. The funds will be used to expand the company's influence in core specialty areas, enter new clinical fields, and enhance AI capabilities, modernizing medical imaging and improving patient care.Bioptimus, a developer of general artificial intelligence foundational models for biology, secures $41 million in fundingOn January 16, Bioptimus, a developer of general artificial intelligence foundational models for biology, secured $41 million in funding led by Cathay Innovation, with participation from Sofinnova Partners, Bpifrance Large Venture Fund, Andera Partners, and others. Bioptimus is building the first general artificial intelligence foundational model for biology to advance scientific research and biotechnological innovation.Brain Tumor Targeted Therapy Developer GT Medical Secures $37 Million in Series D FundingOn January 16, GT Medical, a developer of targeted therapies for brain tumors, secured $37 million in Series D funding, co-led by Evidity Health Capital and Accelmed Partners, with participation from existing investors MVM Partners, Gilde Healthcare, and Medtech Venture Partners. GT Medical plans to use the funds to support the ongoing commercialization of GammaTile.Medical Device Developer Advanced Bifurcation Systems Secures $20.8 Million in Oversubscribed FinancingOn January 21, medical device developer Advanced Bifurcation Systems secured $20.8 million in oversubscribed funding. Advanced Bifurcation Systems has developed a novel technology that enables effective stent placement at bifurcation points in coronary arteries.Percipio Health, a Population Health Monitoring and Management Platform, Secures $20 Million in Series A FundingOn January 21, Percipio Health, a population health monitoring and management platform, secured $20 million in Series A funding, led by UPMC Enterprises, WAVE Ventures, and Labcorp. Percipio's platform uses artificial intelligence and simple smartphones to collect whole-person health signals, enabling real-time assessment and health prediction.Vision Solutions Developer Xianwei Visual Secures Over 100 Million Yuan in Series A FundingOn January 16, Xianwei Vision, a vision solutions developer, secured over RMB 100 million in its Series A round led by Lilly Asia Ventures, with participation from Cowin Capital, Nanjing Innovation Investment Group, and DCP Capital. The proceeds will be used to advance the clinical trials and registration submissions for the "Femtosecond Laser Corneal Refractive Surgery Device," expediting the product’s market entry and commercialization process.Kunpeng Gene, a developer of medical research products, secures over RMB 100 million in Series B financingOn January 17, Kunpeng Gene, a developer of medical research products, secured over 100 million yuan in its Series B financing round, led by Taiping Medical Health Fund, with participation from Anhui Kunhua Fund, some existing shareholders, and the founder. The proceeds from this round will be used to accelerate the R&D, market expansion, and promotion of the company’s multiple innovative product pipelines, including tuberculosis and drug-resistance diagnostics, invasive fungal diagnostics, and respiratory pathogen diagnostics.Scientific Instrument and Equipment R&D, Manufacturer Inspiris Secures Hundreds of Millions in Series C FinancingOn January 18, Insyth Biosciences, a developer and manufacturer of scientific instruments and equipment, secured hundreds of millions of yuan in its Series C financing round, led by the Service Trade Innovation Development Guiding Fund, with participation from Yuanhe Holdings and Luxin Venture Capital. The proceeds from this round will be used to advance the company's innovation in new product pipelines and expand production capabilities, while providing strong momentum for Insyth Biosciences' global strategic layout in the biopharmaceutical field.Xin Zeyuan, a Key Precision Component and Medical Device Consumables R&D and Manufacturer, Secures Nearly RMB100 Million in B+ Round FinancingOn January 20, Xinzeyuan, a key developer and producer of precision components and medical device consumables, secured nearly RMB 100 million in a B+ round of financing jointly invested by Shunbai Fund and Sanmei Investment, with existing shareholder Qiming Venture Partners also participating. Xinzeyuan has broken the technological monopoly of upstream imported manufacturers, establishing a platform focused on the full-chain supply of minimally invasive medical devices. The company serves a wide range of medical brands through four core business modules: rigid endoscopes, flexible endoscopes, endoscopic surgical instruments, and minimally invasive surgical instruments.Rehabilitation Medical Technology Solutions Provider Aoyi Technology Secures Nearly RMB100 Million in B+ Round FinancingOn January 21, Aowill Tech, a provider of rehabilitation medical technology solutions, secured nearly RMB 100 million in a Series B+ funding round led by Huafa Group, with participation from Guangda Huitong and He Ying Capital. The proceeds from this round will help Aowill Tech establish a high-standard production system, completing the final piece of the company’s commercial map. The construction of this production line aims to enhance the company’s core R&D and manufacturing capabilities, expand production capacity, improve delivery performance, and further accelerate the commercial rollout of multiple products in global markets.Medical Analytics Platform Developer IntusCare Secures $11.5 Million in FinancingOn January 16, healthcare analytics platform developer IntusCare secured $11.5 million in funding, led by Deerfield Management with participation from Citi Impact Fund, Jumpstart Nova, and others. The funds will support the launch of CareHub, an integrated care management platform designed to meet the unique needs of Programs of All-Inclusive Care for the Elderly (PACE) and other value-based care models.Women's Health Platform Provider Teal Health Raises $10 Million in Seed FundingOn January 16, women's health platform provider Teal Health secured $10 million in seed funding, led by Emerson Collective and Forerunner, with participation from Serena Ventures, Metrodora, and others. The funds will support the upcoming launch of Teal Wand™, a device currently under FDA review, which is expected to become the first FDA-approved at-home self-collection cervical cancer screening device in the U.S. market.02 Digital Health Industry TrendsHenlius and Deep Potential Technology Launch AI-Assisted Drug Discovery Strategic PartnershipRecently, Henlius and Deep Potential Technology announced a strategic cooperation in AI-assisted drug research and development. The aim is to jointly advance the new drug R&D process by combining artificial intelligence with physical modeling. This collaboration will leverage Deep Potential Technology's technical expertise and project experience in the AI for Science field, as well as the expert knowledge of both parties in drug discovery and AI computing, to provide innovative approaches and methods for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.XtalPi Collaborates with UCB and Deep Principle to Accelerate AI-Driven Drug DevelopmentAilux Biologics, a subsidiary of XtalPi, has signed an AI platform licensing agreement for large molecule drug discovery with UCB, a multinational biopharmaceutical company headquartered in Belgium. Under the agreement, XtalPi has commercially licensed UCB to use Ailux Biologics' self-developed XtalFold™ AI platform for the discovery and engineering design of large molecule drugs. XtalFold™ is an AI-based software platform capable of providing rapid and accurate structural information for large molecule drug development, accelerating innovation across multiple stages of research and development.03 Overview of Global Digital Health M&AOpmabio Acquires CRO Company Pheno BiotechOn the evening of January 16, OPM announced that it had signed an "Equity Acquisition Intent Agreement" with PharmaLegacy Hong Kong Limited, Jiaxing Huituo, and Jiaxing Hetuo, the major shareholders of PharmaLegacy. The agreement stipulates that OPM will acquire control of PharmaLegacy through issuing shares and paying cash. PharmaLegacy is a leading CRO company in China specializing in preclinical efficacy research and evaluation for innovative drug development. It had planned to go public on the STAR Market but withdrew its application. This acquisition will help integrate resources from both sides and enhance competitiveness.ArteryNet/Arterial Orange Industry Think Tank/China Renaissance/China Grand Health/Rock Health/Mobile Health News/Fierce Health, etc.
Compiled by: Liu Shuxia
